Keros Therapeutics Inc.

# Signal Note: OrbiMed Initiates $16.4M Position in KROS OrbiMed's entry into Keros signals confidence in KER-050, the company's lead asset for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder with no approved treatments and ~800 patients in the U.S. The timing suggests positioning ahead of near-term catalysts, likely a regulatory decision on the Phase 2b program or upcoming clinical data that could validate the ALK2 inhibitor approach in this ultra-rare indication with high unmet need and favorable reimbursement dynamics.